EFFICACY OF BRIVARACETAM IN PEDIATRIC EPILEPSY: AN UP-TO-DATE

Among the newest antiepileptic drugs, brivaracetam (BRV), previously known as “ucb34714”, is one of the most interesting molecules available, increasingly getting the attention of researchers. The clinical efficacy of BRV as adjunctive therapy has been extensively assessed in six randomized, control...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Antonio Nicotera
Formato:	article
Lenguaje:	EN
Publicado:	Associazione Italiana Giovani Medici 2021
Materias:	antiepileptic drugs brivaracetam epilepsy children Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/8a459c6dc1de4afab53dabd6fdeebd23
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8a459c6dc1de4afab53dabd6fdeebd23
record_format	dspace
spelling	oai:doaj.org-article:8a459c6dc1de4afab53dabd6fdeebd232021-11-11T18:31:21ZEFFICACY OF BRIVARACETAM IN PEDIATRIC EPILEPSY: AN UP-TO-DATE10.3269/1970-5492.2021.16.322279-7165https://doaj.org/article/8a459c6dc1de4afab53dabd6fdeebd232021-11-01T00:00:00Zhttp://www.embj.org/wp-content/uploads/2021/11/Nicotera_32.pdfhttps://doaj.org/toc/2279-7165Among the newest antiepileptic drugs, brivaracetam (BRV), previously known as “ucb34714”, is one of the most interesting molecules available, increasingly getting the attention of researchers. The clinical efficacy of BRV as adjunctive therapy has been extensively assessed in six randomized, controlled, phase III trials, the results of which demonstrated BRV efficacy in reducing seizures at the dosage of 20–200 mg/day. However, to date, only few data on the pediatric population are available. Here we briefly report the data available on BRV and its usage in the pediatric population suffering from epilepsy to highlight the potential benefits of this drug in this population.Antonio NicoteraAssociazione Italiana Giovani Mediciarticleantiepileptic drugsbrivaracetamepilepsychildrenMedicine (General)R5-920ENEuromediterranean Biomedical Journal, Vol 16, Iss 32, Pp 141-144 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	antiepileptic drugs brivaracetam epilepsy children Medicine (General) R5-920
spellingShingle	antiepileptic drugs brivaracetam epilepsy children Medicine (General) R5-920 Antonio Nicotera EFFICACY OF BRIVARACETAM IN PEDIATRIC EPILEPSY: AN UP-TO-DATE
description	Among the newest antiepileptic drugs, brivaracetam (BRV), previously known as “ucb34714”, is one of the most interesting molecules available, increasingly getting the attention of researchers. The clinical efficacy of BRV as adjunctive therapy has been extensively assessed in six randomized, controlled, phase III trials, the results of which demonstrated BRV efficacy in reducing seizures at the dosage of 20–200 mg/day. However, to date, only few data on the pediatric population are available. Here we briefly report the data available on BRV and its usage in the pediatric population suffering from epilepsy to highlight the potential benefits of this drug in this population.
format	article
author	Antonio Nicotera
author_facet	Antonio Nicotera
author_sort	Antonio Nicotera
title	EFFICACY OF BRIVARACETAM IN PEDIATRIC EPILEPSY: AN UP-TO-DATE
title_short	EFFICACY OF BRIVARACETAM IN PEDIATRIC EPILEPSY: AN UP-TO-DATE
title_full	EFFICACY OF BRIVARACETAM IN PEDIATRIC EPILEPSY: AN UP-TO-DATE
title_fullStr	EFFICACY OF BRIVARACETAM IN PEDIATRIC EPILEPSY: AN UP-TO-DATE
title_full_unstemmed	EFFICACY OF BRIVARACETAM IN PEDIATRIC EPILEPSY: AN UP-TO-DATE
title_sort	efficacy of brivaracetam in pediatric epilepsy: an up-to-date
publisher	Associazione Italiana Giovani Medici
publishDate	2021
url	https://doaj.org/article/8a459c6dc1de4afab53dabd6fdeebd23
work_keys_str_mv	AT antonionicotera efficacyofbrivaracetaminpediatricepilepsyanuptodate
_version_	1718431835624570880

EFFICACY OF BRIVARACETAM IN PEDIATRIC EPILEPSY: AN UP-TO-DATE

Ejemplares similares